| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
2024 Financial Guidance
Incyte is raising the low end of its full year 2024 Jakafi revenue guidance as well as updating its full year 2024 research and development guidance to reflect the ongoing impact of the acquisition of Escient Pharmaceuticals. The research and development guidance excludes $691 million of upfront consideration recorded relating to the acquisition of Escient Pharmaceuticals. Incyte is maintaining its full year 2024 other hematology/oncology revenue guidance, as well as its cost of product revenue and selling, general and administrative guidance. Incyte's guidance is summarized below. Guidance does not include revenue from any potential new product launches or the impact of any potential future strategic transactions.
|
|
Current |
Previous |
|
Jakafi net product revenues |
$2,710 - $2,750 million |
$2,690 - $2,750 million |
|
Other Hematology/Oncology net product revenues(1) |
Unchanged |
$325 - $360 million |
|
GAAP Cost of product revenues |
Unchanged |
7 – 8% of net product revenues |
|
Non-GAAP Cost of product revenues(2) |
Unchanged |
6 – 7% of net product revenues |
|
GAAP Research and development expenses |
$1,755 - $1,800 million |
$1,720 - $1,760 million |
|
Non-GAAP Research and development expenses(3) |
$1,615 - $1,655 million |
$1,580 - $1,615 million |
|
GAAP Selling, general and administrative expenses |
Unchanged |
$1,210 - $1,240 million |
|
Non-GAAP Selling, general and administrative expenses(3) |
Unchanged |
$1,115 - $1,140 million |
Posted In: INCY
